WCLC 2021: Epidemiology of MET Exon 14 mutations

Bookmark and Share
Published: 19 Oct 2021
Views: 3571
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger

Dr Anna Minchom (The Royal Marsden Hospital, London, UK), Dr Alex Spira (Virginia Cancer Specialists Research Institute, Fairfax, USA), Prof Byoung Chul Cho (Yonsei University, Seoul, South Korea) and Prof Albrecht Stenzinger (University Hospital Heidelberg, Heidelberg, Germany) discuss the epidemiology of MET Exon 14 mutations.

Initially, they talk about how to diagnose MET Exon 14 mutant NSCLC and when to test for this type of NSCLC.

They then discuss the best treatments for patients with this mutation and why the method of action of amivantamab is appropriate for these patients.

Prof Cho discusses the initial results from the CHRYSALIS study. Prof Stenzinger talks about the profile of next-generation sequencing (NGS) on MET exon 14 skipping mutation and MET amplification in lung cancer.

Dr Spira mentions the study regarding tepotinib in patients with MET exon 14 skipping NSCLC as identified by liquid or tissue biopsy.

Dr Minchom concludes by talking about the sequencing of PD-1 inhibitors and TKIs in metastatic NSCLC with MET exon 14 skipping mutation and its relationship to survival.

Diagnosing MET exon 14 mutation
Tepotinib in patients with METex14 skipping NSCLC as identified by liquid or tissue biopsy
Initial Results from CHRYSALIS
Amivantamab’s mechanism of action and efficacy
Sequencing of PD-1 inhibitors and TKIs in MET Exon 14 Skipping Mutation NSCLC

This programme is supported by an unrestricted educational grant from Janssen.